Introduction
============

Since the use of prostate specific antigen (PSA) testing, the majority of newly diagnosed prostate cancer (PCa) patients are considered to have low risk of progression ([@r1]). Although PSA screening leads to a PCa mortality reduction, overdiagnosis and overtreatment of these low-risk PCa patients are still a substantial concern ([@r1]-[@r4]). To prevent overtreatment, active surveillance (AS) is increasingly recognized as a favorable alternative to direct radical therapy for men with low-risk PCa ([@r5]-[@r8]). Considering all relevant data, the US Preventive Services Task Force (USPSTF) has recently proposed to endorse physicians to counsel men on PSA screening ([@r9]). This change in the USPSTF recommendation is heavily based on a modeling study which suggests that greater use of AS for low-risk PCa may tilt the balance of benefits and harms in PSA screening in favor of screening ([@r10]). However, this study models a conservative management program without considering the harms of repeated biopsies nor considering the harms of unnecessary treatments which occur despite an AS strategy. Moreover, patients who initially start an AS strategy may switch to active treatment based on signs of progression or other reasons. Furthermore, there is no consensus around the appropriate conduct of AS and differences may exist between strictly controlled cohorts and real life clinical practice ([@r11]). In this study, we analyze long-term follow-up data from the first 500 patients enrolled in the Prostate Cancer Research International Active Surveillance (PRIAS) study, representing real life clinical practice in both community and academic centers from around the world.

Methods
=======

The PRIAS study is a prospective observational study, initiated in December 2006. It facilitates centers around the world in performing AS, by providing a web-based register ([www.prias-project.org](http://www.prias-project.org)) with automatic evidence-based and individualized strategy recommendations ([@r12]). Data entering is done by each participating physician and monitored by the coordinating study center (Erasmus MC, Rotterdam, The Netherlands).

Study population
----------------

We selected the first 500 PRIAS patients, all enrolled before July 2008, to analyze their long-term follow-up data. Patients who already were under surveillance before official initiation of PRIAS were only included if the PRIAS follow-up protocol had been applied. These 500 patients have been part of previous reports ([@r13]-[@r15]).

PRIAS protocol
--------------

The recommended criteria for inclusion were Gleason score (GS) ≤3+3, stage ≤ cT2c, PSA ≤10 ng/mL, ≤2 cores positive for PCa, PSA-density ≤0.2 ng/mL/cm^3^, and fitness for curative treatment ([@r13]). The recommended follow-up strategy during the first 2 years after diagnosis was a PSA test every 3 months and a digital rectal examination (DRE) every 6 months. Thereafter, a PSA test every 6 months and a DRE once yearly was recommended. Standard repeat biopsies were scheduled 1, 4, 7, and 10 years after diagnosis and subsequently every 5 years. Yearly biopsies were only recommended if PSA-doubling time (PSA DT) was between 0 and 10 years. A bone scan was recommended if the PSA level was ≥20 ng/mL. The recommended criteria to switch to active treatment were GS \>3+3 or more than two positive cores on biopsy, and stage higher than cT2. A PSA DT between 0 and 3 years was used to recommend a switch to active treatment until the end of 2014, but was dropped afterwards ([@r13]). Furthermore, the criteria for a switch to active treatment were adapted to incorporate magnetic resonance imaging (MRI) targeted biopsy findings in 2015, as described in a recent publication ([@r13]).

Statistical analyses
--------------------

We performed descriptive statistics to report baseline characteristics, biopsy outcomes, reasons for discontinuation, treatments after discontinuation, outcomes on radical prostatectomy (RP), and biochemical recurrence (BCR), metastases and death rates. Biopsy outcomes were divided in two categories: reclassification based on GS ≥3+4 only and reclassification based on GS ≥3+4 or ≥2 cores positive. RP outcomes were divided in 4 categories: low-risk PCa (GS 3+3, ≤cT2), intermediate-risk PCa Grade Group 2 (GS 3+4, ≤cT2), intermediate-risk PCa Grade Group 3 (GS 4+3, ≤cT2), and high-risk or locally advanced PCa (GS ≥4+4 or ≥T3). BCR was defined as a PSA level ≥0.2 ng/mL after RP or a PSA level 2.0 ng/mL above the nadir after radiation therapy (RT).

Results
=======

The first 500 patients included in PRIAS were followed prospectively by 30 centers across 8 countries ([*Table S2*](#tS.2){ref-type="table"}) until November 20, 2017. At diagnosis, the median age was 65.9 years, the median PSA was 5.3 ng/mL, and most patients had one positive biopsy core (69%) with GS 3+3 (100%) and a clinical stage T1c (80%) ([*Table 1*](#t1){ref-type="table"}). Fifteen patients (3%) did not comply to the recommended inclusion criteria and either had a PSA-density just above 0.2 ng/mL/mL, a PSA just above 10 ng/mL or 3 cores positive for GS 3+3.

###### Patient characteristics at inclusion

  Characteristics            Results
  -------------------------- -------------------
  Age, years                 65.9 (60.0--70.9)
  PSA, ng/mL                 5.3 (3.8--6.7)
  Prostate volume, cm^3^     42.5 (34.6--56.0)
  PSA-density, ng/mL/cm^3^   0.12 (0.08--0.16)
  No. of biopsy cores        8 \[6--10\]
  No. of cores positive      
     1                       345 (69%)
     2                       151 (30.2%)
     \>2                     4 (0.8%)
     Gleason score (3+3)     500 (100%)
  T-stage                    
     cT1c                    400 (80%)
     cT2a                    90 (18%)
     cT2b                    7 (1.4%)
     cT2c                    3 (0.6%)
  Follow-up time, years      6.5 (3.1--8.4)
  No. of follow-up visits    11 \[5--18\]

Data presented as median (IQR) or n (%). PSA, prostate specific antigen; IQR, interquartile range.

During follow-up, a total of 838 biopsies sessions were performed in 427 patients, of which 48% underwent 2 or more surveillance biopsies (range 1--5). Of the remaining 73 patients who did not have a surveillance biopsy, 50 patients discontinued AS based on protocol advice (rising PSA, n=28), anxiety (n=15) or unknown reason (n=7); and 23 patients were lost to follow-up after a median of 3.4 years. Based on the criteria GS ≥3+4 or \>2 cores positive, 79% of the 838 biopsies did not lead to reclassification; based on the criterion GS ≥3+4, 90% of the biopsies would not have led to reclassification ([*Figure 1*](#f1){ref-type="fig"}).
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The median follow-up time, the time between first and last visit, was 6.5 years. After 5 and 10 years of follow-up, respectively, 224 (45%) and 68 (13.6%) patients were still on AS; 181 (36%) and 200 (40%) patients discontinued AS based on protocol advice; 39 (8%) and 48 (9.6%) patients discontinued due to anxiety, on own request or other reasons; 14 (3%) and 19 (3.8%) patients discontinued and were lost to follow-up; 20 (4%) and 55 (11%) patients were switched to watchful waiting (WW) or died; and 22 (4%) and 110 (22%) patients had no recent (\>1 year) data-update ([*Figure 2*](#f2){ref-type="fig"}).
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Among the 500 patients, 325 (65%) discontinued AS after a median of 2.3 years. Subsequently, 112 patients underwent RP, 126 underwent radiotherapy, 57 switched to WW or died, and 30 had another or unknown treatment. RP results of 99 patients were available for analysis. Of the 99 patients, 34% of patients had low-risk PCa (GS 3+3, ≤ cT2) and 33% of patients had intermediate-risk PCa Grade Group 2 (GS 3+4, ≤ cT2), 7% of patients had intermediate-risk PCa Grade Group 3 (GS 4+3, ≤ cT2), and 25% of patients had high-risk or locally advanced PCa (GS ≥4+4 or ≥ T3). Of the patients in the latter two groups, 62.5% had their active treatment within the first 2 years ([*Figure 3*](#f3){ref-type="fig"}).
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Of the total 500 patients, 16 (3.2%) patients had BCR after a median of 2.8 years after RT (n=4) and RP (n=12). Four (0.8%) patients developed metastasis after a median of 1.6 years after discontinuing AS (2 patients had switched to RP, 1 to RT, and 1 to WW). Of the 30 (6%) patients who died, after a median of 4.8 years after diagnosis, 1 patient died due to PCa.

Discussion
==========

AS is increasingly being used and is considered a solution to the widely recognized problem of overtreatment of screening detected low-risk PCa ([@r8],[@r9],[@r16]). The mortality outcomes of AS patients seem comparable to patients who choose direct radical treatment, but possibly with a higher risk of metastasis ([@r17]-[@r19]). Although evidence is not yet conclusive, these findings have led to several guidelines endorsing PSA screening and statements that overdiagnosis does not necessarily lead to overtreatment when AS is used ([@r9],[@r20]).

In this study, we show that AS indeed seems a safe alternative to direct radical therapy, with only 3.2% of patients having BCR after a switch to radical treatment, 0.8% of patients developing metastasis after discontinuing AS, and only one PCa death. However, there are some substantial drawbacks with AS which limit its capability to mitigate all harms associated with overdiagnosing low-risk PCa. In this current analysis, we found that at least 79% of surveillance biopsy sessions performed during follow-up can retrospectively be considered redundant, as they did not show reclassification. During this time period, the criteria for reclassification on biopsy were GS ≥3+4 or ≥2 cores positive. However, in 2016 the PRIAS study omitted the ≥2 positive cores criteria for reclassification because it did not significantly predict unfavorable outcomes on RP ([@r13]). Therefore, retrospectively, the 90% of biopsy sessions without GS ≥3+4 can be considered redundant. Other AS cohorts show similar high rates of biopsy sessions which did not lead to reclassification based on the criteria of GS ≥3+4 ([@r21],[@r22]). Following a prostate biopsy, 0.5% to 6.9% of patients require hospital admission due to severe urinary tract infection or sepsis, and up to 25% experience other complaints ([@r23]), demonstrating that prostate biopsies should be avoided as much as possible.

Furthermore, of the 99 patients who underwent RP, we found that at least one third of patients had favorable pathology (GS3+3, ≤ pT2) which even if left untreated, would not progress ([@r24]). Another third of patients appeared to have intermediate risk PCa Grade Group 2 (GS 3+4, ≤ pT2), for at least some of whom it remains unclear whether they will have benefit from their switch to RP ([@r25]). The remaining one third of patients had unfavorable pathology (GS ≥4+3 or ≥ pT3), for whom a switch to active treatment was appropriate. However, as more than half of these patients had their RP within 2 years after diagnosis, we can assume that these patients were misclassified at diagnosis. As shown in previous analyses of PRIAS patients and other AS cohorts, risk stratification during AS lacks specificity to detect progression or misclassification within the window of curability, with under- and overtreatment as a result ([@r13],[@r26]).

Finally, after 5 and 10 years of follow-up, respectively, 51% and 64% of the 500 patients had discontinued AS. Ten years after diagnosis, only 14% of the patients who originally started AS were confirmed to be still on AS. Of the remaining 22% of patients, no recent update (\>1 year) was available, and these patients should be considered lost to follow-up with the possibility of actually still being on AS or in the meantime having discontinued AS. In other AS cohorts, higher rates of patients still being on AS are reported, with 50% to 63.5% after 10 years ([@r17],[@r18],[@r27]), possibly explained by differences in inclusion and follow-up criteria, and the less strictly controlled PRIAS protocol. Moreover, not all patients who switch to active treatment do so because of protocol based signs of progression. In this study, 48 (18%) of patients switched to active treatment because of anxiety or other reasons, comparable to the 23% of patients in the Johns Hopkins cohort ([@r18]).

This study has some limitations inherent to the initial facilitating setup of this observational study. Some men, for example, were lost to follow-up or did not have a recent data-update. As this is not a strictly controlled cohort, events might have occurred out of our scope. Furthermore, during the follow-up period of these patients, MRI was largely unavailable. Although MRI is more frequently used in contemporary AS strategies, including PRIAS, more data and longer follow-up are needed to evaluate the additional value of MRI in AS to detect misclassification and especially to detect progression ([@r28]-[@r30]). At least for now, MRI is not accurate enough to replace systematic re-biopsies ([@r31]). Future ways to improve the conduct of AS most likely involve incorporation of more sophisticated individualized risk stratification methods, based on MRI and other biomarkers ([@r32],[@r33]).

Based on our findings here, however, AS seems not to solve the problem of overtreatment sufficiently. Therefore, improvement of the diagnostic pathway is an absolute must. With PSA-based screening, benefits (mortality reduction) and harms (unnecessary testing and overdiagnosis) go hand in hand ([@r34]). These harms could, however, be reduced by smarter screening using risk prediction tools to aid in the decision to have a PSA-test or to undergo a prostate biopsy ([@r35]). In addition, other biomarkers and MRI could be incorporated into the diagnostic pathway to secure the detection of potentially lethal PCa ([@r36],[@r37]).

Conclusions
===========

Although AS seems a favorable alternative to direct radical therapy for men with low-risk PCa, the ability of AS to prevent the harms associated with overdiagnosis has not yet been clearly defined in practice. During AS, despite its aim, many in retrospect-unnecessary biopsies are performed and risk stratification methods lack the specificity to prevent all of the overtreatment. Therefore, it remains important to avoid overdiagnosing PCa as much as possible.

###### List of PRIAS study group members, contributing to the data in this paper, by medical center

  Center                                             Country       Members
  -------------------------------------------------- ------------- --------------------------
  Admiraal de Ruyter Ziekenhuis te Goes/Vlissingen   Netherlands   Dr. F.M. Bentvelsen
  Admiraal de Ruyter Ziekenhuis te Goes/Vlissingen   Netherlands   Dr. J. Jaspars
  Albert Schweitzer Ziekenhuis                       Netherlands   Dr. R.M. Potjer
  Albert Schweitzer Ziekenhuis                       Netherlands   Dr. Rene Raaijmakers
  Albert Schweitzer Ziekenhuis                       Netherlands   Dr. W.M. Stomps
  Albert Schweitzer Ziekenhuis                       Netherlands   Dr. J.J. Vis
  Albert Schweitzer Ziekenhuis                       Netherlands   Dr. P.A. Wertheimer
  Albert Schweitzer Ziekenhuis                       Netherlands   Dr. A.G.M. Zeegers
  Amphia Ziekenhuis                                  Netherlands   Dr. P.J. van den Broeke
  Amphia Ziekenhuis                                  Netherlands   D. van der Schoot
  Amphia Ziekenhuis                                  Netherlands   Drs. H. Jansen
  Amphia Ziekenhuis                                  Netherlands   Ilze van Onna
  Amphia Ziekenhuis                                  Netherlands   Dr. E.H.G.M. Oomens
  Amphia Ziekenhuis                                  Netherlands   Dr. P.J. Posthumus
  Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)        Netherlands   E. van Muilekom
  Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)        Netherlands   Dr. H. van der Poel
  BC Cancer Agency                                   Canada        Adam Kahnamelli
  BC Cancer Agency                                   Canada        Alex Briede
  BC Cancer Agency                                   Canada        Dana Matuszewski
  BC Cancer Agency                                   Canada        Henry Lau
  BC Cancer Agency                                   Canada        Devon Poznanski
  Canisius-Wilhelmina Ziekenhuis Nijmegen            Netherlands   Dr. D.M. Somford
  Canisius-Wilhelmina Ziekenhuis Nijmegen            Netherlands   Dr. H. Vergunst
  Catharina Ziekenhuis Eindhoven                     Netherlands   Dr. E.L. Koldewijn
  Catharina Ziekenhuis Eindhoven                     Netherlands   Dr. P.E.F. Stijns
  Catharina Ziekenhuis Eindhoven                     Netherlands   Dr. Wout Scheepens
  Diakonessenhuis Utrecht                            Netherlands   Dr. Karin van Dalen
  Diakonessenhuis Utrecht                            Netherlands   Roan Spermon
  Emco Klinik, Salzburg                              Austria       Dr. Andreas Jungwirth
  Erasmus MC                                         Netherlands   Dr. W. Boellaard
  Erasmus MC                                         Netherlands   Dr. J. Boormans
  Erasmus MC                                         Netherlands   Dr. M.Busstra
  Erasmus MC                                         Netherlands   Prof. Dr. F.H. Schröder
  Erasmus MC                                         Netherlands   Dr. W. Kirkels
  Erasmus MC                                         Netherlands   Dr. Meelan Bul
  Erasmus MC                                         Netherlands   Dr. P. Verhagen
  Erasmus MC                                         Netherlands   Dr. Marij Dinkelman-Smit
  Erasmus MC                                         Netherlands   Wouter Roobol
  Erasmus MC                                         Netherlands   L.D.F. Venderbos
  Erasmus MC                                         Netherlands   A.R. Alberts
  Erasmus MC                                         Netherlands   F-J. H. Drost
  Hospital Virgen del Camino, Pamplona               Spain         Manuel Montesino
  Kuopio University Hospital                         Finland       Sirpa Aaltomaa
  Krankenhaus der Barm. Brueder                      Germany       Prof. Nikolaus Schmeller
  Maasstad Hospital Rotterdam                        Netherlands   Dr. D.C.D. De Lange
  Maasstad Hospital Rotterdam                        Netherlands   Dr. D. van den Ouden
  Medisch Spectrum Twente                            Netherlands   Drs. Emile Alleman
  Medisch Spectrum Twente                            Netherlands   Drs. Boudewijn Santerse
  Medisch Spectrum Twente                            Netherlands   Dr. Henriette Leenknegt
  Medisch Spectrum Twente                            Netherlands   Dr. Maarten-Jan Pit
  Medisch Spectrum Twente                            Netherlands   Sing Khoe
  Oulu University Hospital                           Finland       Pekka Hellström
  Reinier de Graaf Gasthuis                          Netherlands   J. Hoeven
  Rivas Care Group                                   Netherlands   Dr. R. Gilhuis
  Rivas Care Group                                   Netherlands   Dr. H. Plancke
  SIURO - Fondazione IRCCS Istituto                  Italy         Tiziana Magnani
  SIURO - Fondazione IRCCS Istituto                  Italy         Maria Francesca Alvisi
  SIURO - Fondazione IRCCS Istituto                  Italy         Tiziana Rancati PhD
  SIURO - Fondazione IRCCS Istituto                  Italy         Silvia Catania
  St. Franciscus Gasthuis                            Netherlands   Dr. M. Asselman
  St. Franciscus Gasthuis                            Netherlands   Dr. Ilse van den Berg
  St. Franciscus Gasthuis                            Netherlands   Dr. J. Blom
  St. Franciscus Gasthuis                            Netherlands   Dr. E. Boevé
  St. Franciscus Gasthuis                            Netherlands   Dr. R. Nooter
  St. Franciscus Gasthuis                            Netherlands   Dr. J. Rietbergen
  St. Franciscus Gasthuis                            Netherlands   Dr. Stijn de Vries
  University Hospital Muenster                       Germany       Barbara Thielen
  University Hospital Muenster                       Germany       Dr. Sebastian Kemper
  University Hospital Muenster                       Germany       Klaus Kruse
  University Hospital Muenster                       Germany       Dr. A. Semjonow
  University Hospital Muenster                       Germany       Thomas Köpke
  Universitair Ziekenhuis Gent                       Belgium       Prof. W. Oosterlinck
  Vlietland Ziekenhuis                               Netherlands   Drs. Ilse van den Berg
  Vlietland Ziekenhuis                               Netherlands   Drs. Helene Wilkens
  VU Medical Center Amsterdam                        Netherlands   Dr. A.N. Vis
  Westfries Gasthuis                                 Netherlands   Dr. Maicle Leter
  Ziekenhuis Bernhoven                               Netherlands   A.Q.H.J. Niemer
  Ziekenhuisgroep Twente                             Netherlands   Dr. E.B. Cornel
  Ziekenhuisgroep Twente                             Netherlands   Gerd-Jan Molijn

###### Inclusions per center

  Country                                      Center                                                  Inclusions
  -------------------------------------------- ------------------------------------------------------- ------------
  The Netherlands                              Erasmus University Medical Center, Rotterdam            84
  Netherlands Cancer Institute, Amsterdam      54                                                      
  St. Franciscus Hospital, Rotterdam           48                                                      
  Hospital group Twente, Enschede              30                                                      
  Albert Schweitzer Hospital, Dordrecht        44                                                      
  Admiraal de Ruyter Hospital, Goes            21                                                      
  Reinier de Graaf Hospital, Delft             14                                                      
  Medisch Spectrum Twente, Enschede            9                                                       
  Amphia Hospital, Breda                       7                                                       
  Canisius-Wilhelmina Hospital, Nijmegen       7                                                       
  Vlietland Hospital, Rotterdam                7                                                       
  Hospital Bernhoven, Uden                     5                                                       
  Diakonessenhuis, Utrecht                     4                                                       
  VU University Medical Centre, Amsterdam      4                                                       
  Ikazia Hospital, Rotterdam                   2                                                       
  Maasstad Hospital Rotterdam, Rotterdam       2                                                       
  Rivas Care group, Gorinchem                  2                                                       
  Westfries Hospital, Hoorn                    2                                                       
  Catharina Hospital, Eindhoven                1                                                       
  Ruwaard van Putten Hospital, Spijkenisse     1                                                       
  Finland                                      Helsinki University Central Hospital, Helsinki          66
  Kuopio University Hospital, Kuopio           1                                                       
  Oulu University Hospital, Päijät-Häme        1                                                       
  Canada                                       British Columbia Cancer Agency, Vancouver               38
  Italy                                        Fondazione IRCSS Istituto Nazionale dei Tumori, Milan   28
  Germany                                      University Hospital Muenster, Muenster                  6
  Krankenhaus der Barmherzige Brüder, Munich   2                                                       
  Spain                                        Hospital Virgen del Camino, Pamplona                    5
  Austria                                      Emco Klinik, Salzburg                                   4
  Belgium                                      University Hospital Gent, Gent                          1
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